Regulation 31 Certification of manufacturer's licence
The licensing authority must issue a certificate in accordance with the following paragraphs of this regulation in relation to a manufacturer's licence relating to the manufacture or assembly of medicinal products if requested to do so by—
subject to paragraph (5), the holder of the licence;
a person who intends to export a medicinal product manufactured or assembled by the holder under the licence; or
the competent authorities of a country other than F1the United Kingdom into which a medicinal product manufactured or assembled under the licence is, or is proposed to be, imported.
The certificate must contain —
information sufficient to identify the holder of the manufacturer's licence;
details of the medicinal products that may be manufactured or assembled under the licence; and
any other information concerning the holder, the product or the licence that the licensing authority thinks it appropriate to include, including information relating to clinical trials.
If—
a request is made—
under paragraph (1)(a) in relation to the export or the proposed export of a product, or
under paragraph (1)(b) or (c); and
the certificate must be accompanied by the summary of the product characteristics relating to that product.
The licensing authority may restrict the information provided under sub-paragraphs (2)(a) and (b) and paragraph (3) to information relating to the specific medicinal products mentioned in the request made under paragraph (1).
A licence holder who makes a request under paragraph (1) must—
The licensing authority must have regard to the prevailing administrative arrangements of the World Health Organisation when issuing the certificate.
Annotations
Textual amendments
- F1
Words in reg. 31(1)(c) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 24(2); 2020 c. 1, Sch. 5 para. 1(1)
- F2
Words in reg. 31(3)(b) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 24(3) (as substituted by S.I. 2020/1488, reg. 1, Sch. 2 para. 16); 2020 c. 1, Sch. 5 para. 1(1)
- F3
Words in reg. 31(3)(b) omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 13(a)
- F4
Words in reg. 31(5)(a) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 24(3) (as substituted by S.I. 2020/1488, reg. 1, Sch. 2 para. 16); 2020 c. 1, Sch. 5 para. 1(1)
- F5
Words in reg. 31(5)(a) omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 13(b)
- F6
Words in reg. 31(5)(b) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 24(3) (as substituted by S.I. 2020/1488, reg. 1, Sch. 2 para. 16); 2020 c. 1, Sch. 5 para. 1(1)
- F7
Words in reg. 31(5)(b) omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 13(b)
Notes on Part 3
Textual amendments
- F1
Pt. 3 heading and Pt. 3 Ch. 1 inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 4
Notes on Chapter 2
Textual amendments
- F1
Pt. 3 Ch. 2 heading inserted (20.8.2013) by The Human Medicines (Amendment) Regulations 2013 (S.I. 2013/1855), regs. 1(1), 4